Marker Therapeutics (MRKR) EBT (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly EBT of -$4.3 million for Q1 2026, up 10.45% year-over-year from -$3.9 million in Q1 2025, and down 88.19% quarter-over-quarter from -$2.3 million in Q4 2025.
Marker Therapeutics (MRKR) EBT (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported EBT for 17 consecutive years, with -$4.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 10.45% year-over-year to -$4.3 million; the TTM figure through Mar 2026 stood at -$12.7 million (up 14.91% YoY), while the FY2025 annual figure was -$12.2 million, down 14.02% from the prior year.
- EBT eased to -$4.3 million in Q1 2026 per MRKR's latest filing, from -$2.3 million in the prior quarter.
- Across five years, EBT topped out at -$2.0 million in Q3 2025 and bottomed at -$19.9 million in Q2 2022.
- Historically, EBT has averaged -$6.2 million across 5 years, with a median of -$4.1 million in 2025.
- Annual changes were most pronounced in 2023 — EBT soared 77.09% — and 2025, when it slumped 54.05%.
- Marker Therapeutics' EBT stood at -$3.1 million in 2022, then fell by 29.29% to -$4.1 million in 2023, then retreated by 2.76% to -$4.2 million in 2024, then jumped by 45.22% to -$2.3 million in 2025, then tumbled by 88.19% to -$4.3 million in 2026.
- Business Quant data shows MRKR's EBT at -$4.3 million in Q1 2026, -$2.3 million in Q4 2025, and -$2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | -2.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.29 Mn |
| Dec 31, 2025 | -2.28 Mn |
| Sep 30, 2025 | -2.00 Mn |
| Jun 30, 2025 | -4.14 Mn |
| Mar 31, 2025 | -4.80 Mn |
| Dec 31, 2024 | -4.17 Mn |
| Sep 30, 2024 | -2.60 Mn |
| Jun 30, 2024 | -3.39 Mn |
| Mar 31, 2024 | -3.11 Mn |
| Dec 31, 2023 | -4.05 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | -4.55 Mn |
| Mar 31, 2023 | -13.45 Mn |
| Dec 31, 2022 | -3.14 Mn |
| Sep 30, 2022 | -15.39 Mn |
| Jun 30, 2022 | -19.88 Mn |
| Mar 31, 2022 | -10.11 Mn |
| Dec 31, 2021 | -11.40 Mn |
| Sep 30, 2021 | -12.42 Mn |
| Jun 30, 2021 | -26.80 Mn |